The company has since learned the cyberattack was caused by a third-party contractor’s user session within its cloud-based system being compromised.

Xeltis has reached over 50% enrolment in its US pivotal trial of aXess, a vascular access device designed for adults with end-stage renal disease who require haemodialysis.

The test is designed for individuals aged 45 and above who are at average risk for cancer. Credit: tilialucida / Shutterstock.com. Zydus Lifesciences has entered a memorandum of understanding (MoU) ...

Funds will support Materna’s completion of a pivotal trial evaluating its system for reducing pelvic floor muscle injury during childbirth, as well as other commercial activities.

Medicina supplied devices bearing false CE markings to healthcare providers including National Health Service (NHS) Trusts across the UK.

OrthAlign has completed the first clinical procedures using its Lantern ASC system, designed for the ASC setting.

Hyperfine has commercially launched its next-generation Swoop portable MRI system (Model 2) in select European markets.

Aurenar’s V-Link system uses transauricular vagus nerve stimulation to modulate brain inflammation in patients that have experienced a stroke.